Comparison of the effectiveness of different umbilical cord care in infants
A protocol for systematic review and network meta-analysis
Yi Shang, MD\textsuperscript{a}, Yue Sun, MD\textsuperscript{b,∗}

Abstract
Background: More and more studies were performed to explore the effectiveness of umbilical cord care practices. However, the results remain controversial. Hence, the aim of the review was to evaluate and compare the effectiveness of different umbilical cord care in infants through network meta-analysis.

Methods: A systematic literature search for relevant articles published in the English language will be conducted in PubMed, EMBASE, the Cochrane library, and Chinese Biomedical Literature Database from their inception to December 2018. Randomized controlled trials (RCTs) that compared the effectiveness of different types of umbilical cord care practices will be included. Cord infection, illness, and death will be used to assess the clinical effect. Risk of bias assessment of the included RCTs will be conducted by the Cochrane risk of bias tool. The WinBUGS 1.4.3 software will be used to perform the network meta-analysis and the result figures will be generated by STATA V.15.0 software. Grading of recommendations assessment, development, and evaluation will be used to assess the quality of evidence.

Results: The results will be published in a peer-reviewed journal.

Conclusion: This will be the first network meta-analysis to evaluate and compare the effectiveness of different umbilical cord care in infants. Our study will generate evidence of cord care for infants and provide suggestions for clinical practice or guideline.

PROSPERO registration number: CRD42018118052.

Abbreviations: NMA = network meta-analysis, RCT = randomized controlled trial, SMD = standard mean difference, WMD = weighted mean difference.

Keywords: infant, network meta-analysis, systematic review, umbilical cord care

1. Introduction
The death of a child is among the most profoundly stressful events that an adult can experience.\textsuperscript{[1–3]} About 15 million babies are born each year less than 37 weeks pregnant, of whom about 1 million die.\textsuperscript{[4]} More than 30% are caused by infections.\textsuperscript{[5,6]} Some of these infections start as umbilical cord infection. Sources of bacteria that cause umbilical cord infection include the mother’s birth canal, the environment in which the newborn was born Assist the shipper’s hand. Spinal cord infection can be limited to the umbilical cord (umbilical inflammation) or become a systemic infection after entering the blood (eg, neonatal sepsis).

As cord infections should be preventable in most cases,\textsuperscript{[7]} it is important to identify best cord care practices to reduce neonatal mortality and morbidity and offer an alternative to widespread potentially harmful traditional practices.

The World Health Organization and American Academy of Pediatrics recommend good hygiene at delivery and promote dry cord care practice after birth.\textsuperscript{[8,9]} A Cochrane review\textsuperscript{[10]} (n = 69,338 newborns, 22 studies) published in 2013, which found that no antiseptic was found to be advantageous for the prevention of cord infection compared with dry cord care in hospital settings. However, there are anecdotal evidence and experience suggest that health care providers vary in their practice, for example, using alcohol, methylated spirit or povidone-iodine to clean the cord, or dry care without applying anything.\textsuperscript{[11–13]}

Network meta-analysis has been considered to extend conventional meta-analysis on multiple treatments (ie, 3 or more) for a given condition.\textsuperscript{[14]} Compared with pairwise meta-analysis, network meta-analysis allow for visualization of a larger amount of evidence, estimation of the relative effectiveness among all interventions (even if some head to head comparisons are lacking), and rank ordering of the interventions.\textsuperscript{[15]} The value of network meta-analysis (NMAs) for health-care decision making has been recognized and accepted by different health technology assessment and funding agencies worldwide.\textsuperscript{[16,17]}

To help policymakers develop appropriate national guidelines, we will conduct the NMA to define safe and effective topical umbilical cord care for prevention of mortality and cord infections in newborn infants.
2. Methods

2.1. Eligibility criteria

2.1.1. Type of study. Any randomized controlled trial (RCT) regardless of sample size will be included if met the following criteria: infants undergoing umbilical cord care; compare any form of cord care. The RCTs should contain at least one of forms of umbilical cord care. There are no language restrictions.

2.1.2. Type of patients. Newborn infants of any gestation.

2.1.3. Type of interventions. We will include RCTs that reported different forms of umbilical cord care. All interventions must be topical preparation; and interventions include at least 1 form of cord care. The RCTs should contain at least one of forms of umbilical cord care. There are no language restrictions.

2.1.4. Type of outcomes. Primary outcomes

(1) Clinical evidence of localized cord infection: periumbilical erythema, edema, and tenderness;
(2) Clinical evidence of disseminated bacterial infection: fever, meningitis, and septic foci;
(3) All-cause mortality.

Secondary outcomes

(1) Time to cord separation;
(2) Bacterial colonization;
(3) Mother unhappy with treatment.

2.2. Data source

PubMed (from inception to December 2018), EMBASE (from inception to December 2018), the Cochrane library (from inception to December 2018), and Chinese Biomedical Literature Database (from inception to December 2018) will be searched, at the same time, the reference lists of published reviews and retrieved articles will be checked for additional trials.

2.3. Study selection

Two review authors independently screened titles and abstracts of each record retrieved by ENDNOTE. Then, full texts of all potentially relevant studies will be obtained and reviewed for further assessment. Disagreements were discussed or by a third reviewer if no consensus was reached. We will use predefined extraction forms with detailed written instructions which will be created using Microsoft Excel 2013 to collect relevant information and data. Data will be extracted from eligible studies including publication details, general characteristics of include trials (name of first author, year of publication, number of centers, setting, and total sample size), details of participants (gender, age, and country), and intervention characteristics as well as outcomes. Any missing data will be acquired by contacting the author by email or telephone.

2.4. Search strategy

The key search terms are Umbilical Cord, Infant, Ethanol, Chlorhexidine, Anti-Bacterial Agents, Iodine, Acriflavine, Gentian Violet, Dry, Hexachlorophene, Nitrofurazone, Tetracycline, and Tetracycline.

Search strategy of PubMed was as follows:

#1 “Umbilical Cord” [Mesh]
#2 Umbilical Cord [Title/Abstract] OR Umbilical-Cord [Title/Abstract] OR umbilicus [Title/Abstract] OR Umbilical Cords [Title/Abstract]
#3 #1 OR #2
#4 “Infant” [Mesh]
#5 Infant [Title/Abstract] OR newborn [Title/Abstract] OR neonate [Title/Abstract] OR prematurity [Title/Abstract] OR preterm [Title/Abstract] OR premature [Title/Abstract]
#6 #4 OR #5
#7 “Ethanol” [Mesh] OR “alcohol” [Mesh]
#8 Ethanol [Title/Abstract] OR EtOH [Title/Abstract] OR alcohol [Title/Abstract]
#9 “Chlorhexidine” [Mesh]
#10 Chlorhexidine [Title/Abstract] OR CHX [Title/Abstract] OR CHD [Title/Abstract]
#11 “Anti-Bacterial Agents” [MeSH]
#12 Anti-Bacterial Agents [Title/Abstract] OR anti-infective agents [Title/Abstract] OR antibacterial agents [Title/Abstract] OR anti-infective gent [Title/Abstract] OR anti-sepsis agent [Title/Abstract] OR anti-sepsis agents [Title/Abstract] OR antimicrobial agent [Title/Abstract] OR antimicrobial agents [Title/Abstract] OR antiseptic [Title/Abstract]
#13 “Iodine” [Mesh]
#14 Iodine [Title/Abstract] OR povidone-iodine [Title/Abstract]
#15 “acriflavine” [Mesh]
#16 acriflavine [Title/Abstract]
#17 Gentian Violet [Title/Abstract]
#18 dry [Title/Abstract] OR drying [Title/Abstract]
#19 “hexachlorophene” [Mesh]
#20 hexachlorophene [Title/Abstract]
#21 “Nitrofurazone” [Mesh]
#22 Nitrofurazone [Title/Abstract]
#23 “Tetracycline” [Mesh]
#24 Tetracycline [Title/Abstract]
#25 OR /7-24
#26 “Clinical Trials, Phase II as Topic” [Mesh] OR “Clinical Trials, Phase III as Topic” [Mesh] OR “Clinical Trials, Phase IV as Topic” [Mesh] OR “Controlled Clinical Trials as Topic” [Mesh] OR “Randomized Controlled Trials as Topic” [Mesh] OR “Intention to Treat Analysis” [Mesh] OR “Pragmatic Clinical Trials as Topic” [Mesh] OR “Clinical Trials, Phase II” [Publication Type] OR “Clinical Trials, Phase III” [Publication Type] OR “Controlled Clinical Trials” [Publication Type] OR “Randomized Controlled Trials” [Publication Type] OR “Pragmatic Clinical Trials as Topic” [Publication Type] OR “Single-Blind Method” [Mesh] OR “Double-Blind Method” [Mesh]
#27 random*[Title/Abstract] OR blind*[Title/Abstract] OR singleblind*[Title/Abstract] OR doubleblind*[Title/Abstract] OR trebleblind*[Title/Abstract] OR tripleblind*[Title/Abstract]
#28 #26 OR #27
#29 #3 AND #6 AND #25 AND #28

2.5. Risk of bias of individual studies

Two of the reviewers independently used the Cochrane Handbook V.5.1.0 for systematic reviews of intervention to assess the quality of included RCTs. 15 We will resolve any
disagreement by discussion or by involving a third review author which was composed of 6 domains: random sequence generation, allocation concealment, blinding of all participants, including patients, personnel and outcome assessors, incomplete outcome data, selective reporting, and other sources of bias. We will evaluate the methodological quality as low, high or unclear risk of bias. Bias in RCTs will be evaluated for 7 domains: method of random sequence generation (selection bias), allocation concealment (selection bias), participant and personnel blinding (performance bias), outcome assessment blinding (detection bias), incomplete data (detection bias), selective reporting (detection bias), and other bias. Each RCT will be classified as having a high, low, or unclear risk of bias.

2.6. Statistical analysis

2.6.1. Pairwise meta-analysis. For dichotomous outcomes, we calculated the average odds ratio with the 95% confidence interval (CI); for continuous outcomes, we calculated the average standard mean difference (or the weighted mean difference if all trials use the same scale) with the 95% CI. We will assess statistically the presence of heterogeneity within each pair-wise comparison using the $I^2$ statistic and its 95% CI that measures the percentage of variability that cannot be attributed to random error.\[^{13}\] If the $P$ value $\geq 0.1$ and $I^2 \leq 50\%$, it suggests that there is no statistical heterogeneity, and the Mantel-Haenszel fixed effects model will be used for meta-analysis. If the $P$ value $< 0.1$ and $I^2 \geq 50\%$, we will perform only subgroup analyses without calculating an overall estimate. Begg and Egger funnel plot method will be performed to help distinguish asymmetry due to publication bias when applicable.\[^{18,19}\]

2.6.2. Network meta-analysis. The NMA will be performed in a Bayesian hierarchical framework using Markov Chain Monte Carlo method in WinBUGS 14 (MRC Biostatistics Unit, Cambridge University, UK).\[^{20}\] We will use the node splitting method to examine the inconsistency between direct and indirect comparisons if a loop connecting 3 or more arms exist.\[^{21}\] To rank the treatments according to each outcome accounting for the uncertainty in the treatment effects, we used the surface under each outcome accounting for the network plot will be drawn to describe and present the geometry of the treatment network of comparisons across trials to ensure if the network meta-analysis is feasible. All the result of the treatment network of comparisons if a loop connecting 3 or more arms exist.\[^{21}\] To evaluate the methodological quality as low, high or unclear risk of bias. Bias in RCTs will be evaluated for 7 domains: method of random sequence generation, allocation concealment, blinding of all participants, including patients, personnel and outcome assessors, incomplete outcome data, selective reporting, and other sources of bias. Each RCT will be classified as having a high, low, or unclear risk of bias.

2.7. Quality of evidence

We will assess the quality of the evidence using the grading of recommendations assessment, development, and evaluation (GRADE) approach as outlined in the GRADE handbook in order to assess the quality of the body of evidence. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of the body of evidence for each outcome. It is classified into 4 levels: high level, moderate level, low level, and very low level.

3. Discussion

It is important to identify best cord care practices to reduce neonatal mortality and morbidity and offer an alternative to widespread potentially harmful traditional practices. To the best of our knowledge, this is the first network meta-analysis protocol comparing the effectiveness of different forms of umbilical cord care.

This NMA will summarize the direct and indirect evidence to evaluate and compare the effectiveness of different umbilical cord care in infants. Furthermore, we will assess the quality of evidence using the GRADE framework. We hope that our study will generate evidence of cord care for infants and provide suggestions for clinical practice or guideline.

Author contributions

YS and YS planned and designed the study. YS and YS tested the feasibility of the study. YS and YS provided methodological advice, considered for ideas and overall structure of the article and revised the manuscript. YS and YS wrote the manuscript. All authors approved the final version of the manuscript.

Data curation: Yi Shang, Yue Sun.
Methodology: Yi Shang, Yue Sun.
Supervision: Yi Shang, Yue Sun.
Writing – review and editing: Yi Shang, Yue Sun.

Yue Sun orcid: 0000-0002-3974-2090.

References

[1] Koopmans L, Wilson T, Cacciaprete J, et al. Support for mothers, fathers and families after perinatal death. Cochrane Database Syst Rev 2013;19: CD000432.
[2] Li J, Laursen TM, Proctor DH, et al. Hospitalization for mental illness among parents after the death of a child. N Engl J Med 2005;352: 1190–6.
[3] Rogers CH, Floyd FJ, Seltzer MM, et al. Long-term effects of the death of a child on parents’ adjustment in midlife. J Fam Psychol 2008;22:203–11.
[4] Rabe H, Díaz-Rossel JL, Duley L, et al. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes. Cochrane Database Syst Rev 2012;15:CD003248.
[5] Lawn JE, Cousens S, Zupan J, et al. 4 million neonatal deaths: when? Where? Why? Lancet 2005;365:891–900.
[6] Mullany LC, Darmstadt GL, Katz J, et al. Risk of mortality subsequent to umbilical cord infection among newborns of southern Nepal: cord infection and mortality. Pediatr Infect Dis J 2009;28:17–20.
[7] Capurro H. Topical Umbilical Cord Care at Birth: RHL Commentary. 2004;The WHO Reproductive Health Library,
[8] AAP Committee on Infectious DiseasesRed Book: A Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003.
[9] World Health OrganizationCare of the Umbilical Cord: A Review of the Evidence. WHO, Maternal and Newborn Health Safe Motherhood. Geneva: WHO; 1999.
[10] Imdad A, Bautista RM, Senen KA, et al. Umbilical cord antiseptics for preventing sepsis and death among newborns. Cochrane Database Syst Rev 2013;5:CD008635.
[11] Giras-Le Guen C, Caille A, Laumay E, et al. Dry care versus antiseptics for umbilical cord care: a cluster randomized trial. Pediatrics 2017;139: e20161857.
[12] Karumbi J, Mulaku M, Aluvaala J, et al. Topical umbilical cord care for prevention of infection and neonatal mortality. Pediatr Infect Dis J 2014;32:78–83.
[13] Ozdemir H1, Bilgen H, Topuzoglu A, et al. Impact of different antiseptics on umbilical cord colonization and cord separation time. J Infect Dev Ctries 2017;11:152–7.
[14] Li L, Catalá-López F, Alonso-Arroyo A, et al. The global research collaboration of network meta-analysis: a social network analysis. PLoS One 2016;11:e0163239.
[15] Bafeta A, Trinquart L, Soror R, et al. Reporting of results from network meta-analyses: methodological systematic review. BMJ 2014;348:g1741.
[16] Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the
[17] Tian JH, Zhang J, Ge L, et al. The methodological and reporting quality of systematic reviews from China and the USA are similar. J Clin Epidemiol 2017;85:30–8.
[18] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1084–101.
[19] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.

[20] Lunn DJ, Thomas A, Best N, et al. WinBUGS — a Bayesian modeling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325–37.
[21] Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105–24.
[22] Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012;3:80–97.